Brief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
29/09/2026 12:07
BRIEF-Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311 Sept 29 (Reuters) - Invivyd, Inc. IVVD.O:
INVIVYD ANNOUNCES POSITIVE TOPLINE RESULTS FROM LIBERTY PHASE 3 STUDY DEMONSTRATING VYD2311 SAFETY AND TOLERABILITY SUPERIOR TO MRNA-BASED COVID-19 VACCINE; ANNOUNCES REGULATORY SUBMISSION PLANS FOR VYD2311
INVIVYD, - VYD2311 COMBINED WITH MRNA COVID-19 VACCINE ADDS TO NEUTRALIZING TITERS WITHOUT INTERFERENCE
INVIVYD, - PLANS BLA SUBMISSION FOR VYD2311 TO FDA VIA ACCELERATED APPROVAL PROGRAM
INVIVYD, - VYD2311 DEMONSTRATES SAFETY AND TOLERABILITY SUPERIOR TO MRNA-BASED COVID-19 VACCINE
Source text: ID:nGNXc56Fw2
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview